Last reviewed · How we verify
EV71 inactived vaccine（Vero cells）
EV71 inactived vaccine（Vero cells） is a inactivated viral vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71, Prevention of EV71-associated neurological complications in infants and young children.
This inactivated virus vaccine stimulates the immune system to produce antibodies and cellular immunity against enterovirus 71 (EV71) to prevent infection and disease.
This inactivated virus vaccine stimulates the immune system to produce antibodies and cellular immunity against enterovirus 71 (EV71) to prevent infection and disease. Used for Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71, Prevention of EV71-associated neurological complications in infants and young children.
At a glance
| Generic name | EV71 inactived vaccine（Vero cells） |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | inactivated viral vaccine |
| Target | Enterovirus 71 (EV71) viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains chemically inactivated EV71 virus particles grown in Vero cells (monkey kidney cells). Upon intramuscular injection, the inactivated viral antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize live EV71 virus upon natural exposure. This prevents or reduces the severity of hand, foot, and mouth disease (HFMD) and other EV71-associated complications.
Approved indications
- Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71
- Prevention of EV71-associated neurological complications in infants and young children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Loss of appetite
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EV71 inactived vaccine（Vero cells） CI brief — competitive landscape report
- EV71 inactived vaccine（Vero cells） updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about EV71 inactived vaccine（Vero cells）
What is EV71 inactived vaccine（Vero cells）?
How does EV71 inactived vaccine（Vero cells） work?
What is EV71 inactived vaccine（Vero cells） used for?
Who makes EV71 inactived vaccine（Vero cells）?
What drug class is EV71 inactived vaccine（Vero cells） in?
What development phase is EV71 inactived vaccine（Vero cells） in?
What are the side effects of EV71 inactived vaccine（Vero cells）?
What does EV71 inactived vaccine（Vero cells） target?
Related
- Drug class: All inactivated viral vaccine drugs
- Target: All drugs targeting Enterovirus 71 (EV71) viral antigens
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of hand, foot, and mouth disease (HFMD) caused by enterovirus 71
- Indication: Drugs for Prevention of EV71-associated neurological complications in infants and young children